Industry

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022. The company develops and commercializes blood-based diagnostic tests designed to address important unmet needs in healthcare, by combining … [Read more…]

UPB-101 is a thymic stromal lymphopoietin receptor (TLSPR) blocker that inhibits signaling at the top of the inflammatory cascade WALTHAM, Mass.–(BUSINESS WIRE)–Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the … [Read more…]

Researchers find that doctors underestimate and caregivers overestimate symptoms LOS ANGELES–(BUSINESS WIRE)–A recent study reveals differences in how symptom toxicity is reported for children receiving cancer treatment in clinical trials. Doctors often underestimate or miss a child’s symptoms, while caregivers tend to overestimate symptoms. Children’s Hospital Los Angeles was one of nine hospitals that participated … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis, historical and forecasted … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029” report has been added to ResearchAndMarkets.com’s offering. Industry Outlook Dravet syndrome treatment accounted for a market value of US$ 258.1 Mn in 2020 and projected to grow at a CAGR of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Chronic Kidney Disease – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Chronic Kidney Disease- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the … [Read more…]

FRANKFURT AM MAIN & LONDON–(BUSINESS WIRE)–Akanda Corp. (“Akanda”) (NASDAQ: AKAN) and Cansativa GmbH (“Cansativa Group”) today jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars. This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda’s EU-GMP certified indoor grow … [Read more…]

A survey of 1,012 UK doctors has found that nearly half of junior doctors intend to pursue non-clinical careers The top reason (37%) is burnout, but this is not directly linked to the COVID-19 pandemic Almost 3 in 10 respondents (29%) mentioned that they would like to make a career change, with female doctors more … [Read more…]

BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic Regulation (IVDR), and will be required for products sold within the EU from May 2022 onward. A transitional regulation allows established, non-IVDR-certified products to be sold and used if they … [Read more…]

TORONTO–(BUSINESS WIRE)–First paragraph, first sentence of release should read: Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced today that it has established an at-the-market equity program (the “ATM Program”) that allows Cybin to issue and sell up to USD$35,000,000 of common shares … [Read more…]